Purpose: The nucleoside analog, gemcitabine, has shown activity as a single agent in the treatment of metastatic non-small-cell lung cancer (NSCLC). Its combination with cisplatin in preclinical models suggested synergy between the two drugs. The aim of the study was to evaluate the clinical efficacy and toxicity of the cisplatin-gemcitabine combination in advanced NSCLC.
Patients And Methods: Forty-eight consecutive previously untreated NSCLC patients entered the trial from January to June 1994. The median age was 60 years (range, 37 to 70) and performance status (PS) was 0 or 1; 22 patients had unresectable stage III disease (21 stage IIIB and one stage IIIA) and 26 had stage IV disease. Gemcitabine 1 g/m2 was administered weekly (days 1, 8, and 15) followed by a 1-week rest and cisplatin 100 mg/m2 on day 2 of each 28-day cycle. Survival and response were determined in accordance with the intention-to-treat principle in all enrolled patients.
Results: Of 48 assessable patients, one (stage IV) had a complete response (CR) and 25 achieved a partial response (PR). The overall response rate was 54% (95% confidence interval [CI], 40% to 68%). Thrombocytopenia was the main side effect, with 52% of patients experiencing grade III to IV toxicity, which was usually short-lived and responsible for the omission of gemcitabine administration on day 15 in 50% of chemotherapy courses. The median survival time was 61.5 weeks (95% CI, 40 to 71).
Conclusion: The combination of gemcitabine and cisplatin induced a high response rate in both stage IIIB and IV NSCLC, with modest side effects. The regimen deserves further careful evaluation in a phase III prospective randomized trial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.1997.15.1.297 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy and tolerability, we conducted a retrospective analysis of its first-line treatment outcomes.
Methods: We included patients with unresectable, locally advanced, or metastatic BTC treated with cisplatin, gemcitabine, plus durvalumab.
Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis.
Gynecol Oncol
December 2024
Department of Gynecology, Osaka International Cancer Institute, Osaka, Japan. Electronic address:
Article Synopsis
- The study aimed to explore the impact of adjuvant chemotherapy on survival rates in patients diagnosed with stage I uterine leiomyosarcoma (uLMS).
- A systematic review of 16 studies, involving nearly 5,700 patients, found that adjuvant chemotherapy was used by about 38.5% of patients but showed no significant difference in overall survival or disease-free survival compared to those who received observation only.
- Despite a variety of chemotherapy regimens being assessed, including drugs like doxorubicin and cisplatin, results indicated no clear survival advantage from using adjuvant chemotherapy in these patients.
Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT).
J Gastrointest Cancer
October 2024
Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 226014, India.
Article Synopsis
- The study investigates the outcomes of gallbladder cancer (GBC) patients with retroperitoneal lymphadenopathy (RPLN), analyzing their response to treatment via chemotherapy followed by consolidation chemoradiotherapy (CTRT).
- It focuses on a group of 189 patients, of which 80 had RPLN, comparing their treatment responses and overall survival rates to those without RPLN, noting their similar demographic characteristics.
- Results indicated that while both groups had comparable response rates to treatment, overall survival was further analyzed using statistical methods, highlighting a complex treatment dilemma for patients with RPLN in locally advanced non-metastatic GBC.
Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach.
Diagnostics (Basel)
September 2024
Department of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Edobashi 2-174, Tsu 514-8507, Mie, Japan.
Article Synopsis
- A 54-year-old woman with Stage IIIb squamous cell carcinoma initially underwent chemoradiotherapy but faced cancer relapse two years later, leading to treatment with nivolumab, which was stopped due to drug-induced pneumonitis.
- After several unsuccessful treatments, including prednisolone and multiple cytotoxic agents, the patient received a combination therapy of cisplatin, gemcitabine, and necitumumab, followed by palliative radiation for lymph node enlargement.
- Remarkably, a treatment with atezolizumab resulted in significant tumor regression, suggesting earlier treatments may have influenced PD-L1 expression, highlighting the need for more research into treatment history's impact on therapy effectiveness in squamous cell carcinoma.
mFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC/GS/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: A single-center retrospective cohort study.
Biosci Trends
January 2025
Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Institute for Precision Medicine, Key Laboratory of Digital Intelligence Hepatology (Ministry of Education), Tsinghua University; Research Unit of Precision Hepatobiliary Surgery Paradigm, Chinese Academy of Medical Sciences, Beijing, China.
Biliary tract tumors (BTC) account for about 3% of all digestive system tumors, with rising incidence and limited treatment options, particularly for advanced stages, underscoring the need for innovative therapies. This retrospective cohort study evaluated the safety and efficacy of a novel regimen combining hepatic artery infusion chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX-HAIC) alongside lenvatinib and programmed cell death protein-1 (PD-1) inhibitors (mFOLFOX-HAIC+lenvatinib+PD-1i) compared to standard regimens of gemcitabine plus cisplatin, gemcitabine plus S1, or gemcitabine plus oxaliplatin (GC/GS/GEMOX) in advanced BTC patients treated from March 2019 to November 2023. A total of 89 patients were analyzed, with 55 receiving hepatic arterial infusion chemotherapy and 34 receiving the GC/GS/GEMOX regimens.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!